Shufflon protein B Antibody

What is Shufflon protein B (Shb) and what is its biological significance?

Shufflon protein B (Shb) functions as a platform protein involved in receptor tyrosine kinase signaling pathways. Despite its importance in cellular signaling, the complete function of Shb remains incompletely characterized, making it an active area of research. Understanding Shb function requires reliable detection methods, which have been challenging due to issues with antibody specificity and sensitivity . The protein likely serves as an adapter in multiple signaling complexes, making its reliable detection crucial for elucidating its various cellular roles. Researchers investigating receptor tyrosine kinase pathways should consider Shb as a potential mediator in their signaling cascades of interest.

What cell lines are recommended for studying endogenous Shb expression?

HEK 293T cells express Shb at both mRNA and protein levels, making them a suitable model system for Shb research. This has been confirmed through ProteomeScout analysis (Probeset ID: 204656-at) . When establishing new experimental systems, researchers should verify Shb expression in their chosen cell lines using validated detection methods. Expression levels may vary across different cell types and under different experimental conditions, necessitating careful characterization before proceeding with functional studies. Western blotting using validated antibodies can confirm protein expression, while RT-PCR can verify mRNA expression.

What are the fundamental challenges in detecting Shb in experimental settings?

The primary challenges in Shb detection relate to antibody specificity and sensitivity issues. Many commercial antibodies show significant shortcomings or are entirely unsuitable for detecting endogenous Shb . These limitations necessitate thorough validation before experimental use. The few antibodies capable of detecting Shb typically work in either western blotting or immunoprecipitation experiments, but not both, further complicating experimental design . This application-specific functionality requires researchers to carefully select antibodies based on their intended experimental approach rather than assuming universal applicability.

How should researchers select appropriate anti-Shb antibodies for specific applications?

Selection of anti-Shb antibodies should be guided by the intended experimental application. For applications requiring native protein conformation (such as immunoprecipitation and flow cytometry), antibodies targeting conformational epitopes are generally preferred . Conversely, for methods involving denatured proteins (western blotting, immunocytochemistry, and immunohistochemistry), antibodies targeting linear epitopes typically perform better . The epitope location also matters—antibodies targeting different regions of Shb (N-terminal versus C-terminal) may exhibit different specificities and sensitivities. Prior validation in the specific application of interest is essential, as performance can vary dramatically between experimental approaches.

What commercial anti-Shb antibodies are available and what epitopes do they target?

Several commercial antibodies are available for Shb detection, each targeting different epitopes. The table below summarizes key commercially available anti-Shb antibodies:

Each antibody targets a specific region of Shb, which may affect its performance in different experimental contexts .

How do epitope characteristics influence antibody performance in different applications?

The specific epitope targeted by an anti-Shb antibody significantly influences its performance across different applications. Antibodies recognizing linear epitopes perform better in applications where proteins are denatured, such as western blotting and immunohistochemistry . This is because the linear amino acid sequence remains accessible after denaturation. Conversely, antibodies targeting conformational epitopes are more effective for applications maintaining native protein structure, such as immunoprecipitation and flow cytometry . The specific location of the epitope (N-terminal versus C-terminal) can also affect antibody performance, as some regions may be more accessible than others in the native or denatured protein.

What validation strategies should be employed before using anti-Shb antibodies?

Comprehensive validation of anti-Shb antibodies should include testing across multiple applications to determine application-specific performance. Researchers should:

• Test antibodies in both western blotting and immunoprecipitation experiments, recognizing that performance may differ between applications .

• Include appropriate positive controls (such as HEK 293T cells known to express Shb) and negative controls (preferably Shb-knockout cells).

• Validate antibody specificity through peptide competition assays or siRNA knockdown experiments.

• Evaluate sensitivity by detecting varying concentrations of purified protein or endogenous Shb.

• Consider cross-reactivity with related proteins through computational analysis of epitope conservation.

This multi-faceted approach ensures reliable and reproducible results in subsequent experiments .

What is the recommended protocol for western blotting detection of Shb?

For optimal western blotting detection of Shb:

• Perform SDS-PAGE using a 5% stacking gel and 15% separating gel to achieve appropriate protein resolution .

• Transfer proteins to polyvinylidene difluoride (PVDF) membrane using standard transfer conditions .

• Block the membrane with an appropriate blocking buffer (typically containing bovine serum albumin).

• Incubate with primary anti-Shb antibody at the recommended concentration (1 μg/ml for SAB2104743 and ab94851, or 1/1000 dilution for ab175553 and ab129190) .

• Wash thoroughly and incubate with appropriate species-specific secondary antibody conjugated with horseradish peroxidase.

• Develop using enhanced chemiluminescence detection system and H₂O₂ as substrate .

• Document results using appropriate imaging systems and include molecular weight markers to confirm the expected size of Shb.

How can immunoprecipitation experiments be optimized for Shb detection?

For effective immunoprecipitation of Shb:

• Lyse cells in an appropriate buffer (e.g., 20 mM Tris-HCl, 50 mM NaCl, 0.05% Triton X-100, 1% bovine serum albumin, pH 8.0) .

• Include protease inhibitors (pepstatin, leupeptin, and phenylmethylsulfonyl fluoride) to prevent protein degradation .

• Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Incubate cleared lysates with anti-Shb antibodies verified for immunoprecipitation applications.

• Capture antibody-protein complexes using protein A/G beads or other appropriate affinity matrices .

• Wash extensively to remove non-specific interactions.

• Elute bound proteins using SDS-PAGE loading buffer and analyze by western blotting with a different anti-Shb antibody targeting a distinct epitope .

This approach minimizes background and maximizes specific Shb detection.

How should researchers interpret contradictory results from different anti-Shb antibodies?

When faced with contradictory results from different anti-Shb antibodies, researchers should consider several factors:

• Epitope accessibility: Different epitopes may be differentially exposed depending on experimental conditions or protein conformation .

• Application suitability: Some antibodies work only in specific applications (western blotting versus immunoprecipitation) .

• Specificity limitations: Antibodies may cross-react with related proteins or detect non-specific bands.

• Sensitivity thresholds: Different antibodies have varying detection limits for Shb.

To resolve contradictions, researchers should:

• Compare results using multiple antibodies targeting different epitopes

• Validate findings with complementary approaches (e.g., mass spectrometry)

• Include appropriate positive and negative controls

• Consider species differences if working with human versus mouse Shb

What controls are essential for validating Shb detection experiments?

Essential controls for Shb detection experiments include:

• Positive controls: Cell lines known to express Shb, such as HEK 293T cells .

• Negative controls: Ideally Shb-knockout cells or tissues, or alternatively, cells with confirmed low/no Shb expression.

• Specificity controls: Peptide competition assays using the immunizing peptide to confirm antibody specificity.

• Loading controls: Housekeeping proteins to normalize for total protein loading in western blots.

• Secondary antibody controls: Samples processed with secondary antibody only to identify non-specific binding.

• siRNA/shRNA knockdown controls: To confirm the identity of detected bands through reduced signal intensity.

These controls help distinguish genuine Shb detection from experimental artifacts and non-specific binding.

How can researchers address false positives in Shb detection?

Addressing false positives in Shb detection requires a multi-faceted approach:

• Validate with multiple antibodies: Use several anti-Shb antibodies targeting different epitopes to confirm results .

• Employ complementary techniques: Combine western blotting with immunoprecipitation or mass spectrometry.

• Include peptide competition: Pre-incubate antibodies with immunizing peptides to block specific binding.

• Implement genetic validation: Use Shb knockdown or knockout systems to confirm signal specificity.

• Optimize blocking conditions: Adjust blocking reagents and durations to minimize non-specific binding.

• Increase washing stringency: More thorough washing can reduce background signals.

• Consider post-translational modifications: These may affect antibody recognition and produce variable results.

This comprehensive approach minimizes false positives and increases confidence in experimental findings.

How can phage display techniques improve antibody development for Shb detection?

Phage display offers significant advantages for developing improved Shb antibodies:

• Library screening: Phage display allows screening of large antibody libraries against Shb epitopes to identify highly specific binders .

• Affinity maturation: The technique enables selection of antibodies with progressively higher affinity through multiple rounds of selection .

• Epitope targeting: Researchers can direct selection toward specific Shb domains or epitopes of interest.

• Cross-reactivity elimination: Negative selection steps can remove antibodies that bind to related proteins.

• Customized specificity: High-throughput sequencing and computational analysis can identify antibodies with desired specificity profiles for Shb .

This approach could yield antibodies with improved specificity and sensitivity for Shb detection across multiple applications.

What computational approaches can enhance antibody design for improved Shb specificity?

Advanced computational approaches offer powerful tools for designing Shb-specific antibodies:

• Biophysics-informed models: These can identify and disentangle multiple binding modes associated with specific ligands .

• Binding mode prediction: Computational analysis can predict antibody-epitope interactions and optimize binding affinity .

• Specificity profiling: Models can design antibodies with customized specificity profiles, either highly specific for Shb or cross-reactive with defined related proteins .

• Library design: Computational tools can guide the design of focused antibody libraries with higher likelihood of containing Shb-specific binders.

• Epitope mapping: In silico approaches can identify unique Shb epitopes unlikely to cross-react with related proteins.

The integration of experimental data with computational modeling provides a powerful approach for developing next-generation Shb antibodies with improved performance characteristics .

How might advances in protein expression systems impact Shb antibody development?

Emerging protein expression systems could significantly advance Shb antibody development:

• Cell-free systems may enable expression of difficult-to-produce Shb fragments for immunization and screening.

• Mammalian expression systems ensure proper folding and post-translational modifications of Shb for antibody development.

• Novel display technologies like ribosome display or yeast display provide alternative platforms for selecting Shb-specific antibodies.

• Recombinant antibody production enables precise control over antibody format and properties.

• Site-specific conjugation techniques allow development of optimally labeled anti-Shb antibodies for various applications.

These advances in protein expression and engineering could overcome current limitations in Shb antibody specificity and application range.